Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Terns Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
TERN
Nasdaq
8731
https://ternspharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Terns Pharmaceuticals Inc
Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans
- Apr 14th, 2024 2:16 pm
Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
- Apr 10th, 2024 8:05 pm
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
- Mar 14th, 2024 8:05 pm
Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia
- Mar 11th, 2024 8:05 pm
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
- Mar 7th, 2024 9:05 pm
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
- Feb 27th, 2024 9:05 pm
Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4)
- Feb 7th, 2024 9:05 pm
Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer
- Feb 7th, 2024 1:05 pm
Terns Pharmaceuticals to Highlight 2024 Priorities and Clinical Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
- Jan 4th, 2024 9:05 pm
Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit
- Nov 29th, 2023 9:05 pm
Terns Pharmaceuticals Mourns the Loss of Senthil Sundaram, Former Chief Executive Officer
- Nov 27th, 2023 9:05 pm
Terns Pharmaceuticals Inc (TERN) Reports Q3 2023 Financials and Corporate Progress
- Nov 14th, 2023 5:16 pm
Terns Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Updates
- Nov 14th, 2023 1:05 pm
Terns Pharmaceuticals Presents Late-Breaking Data from Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH at AASLD The Liver Meeting® 2023
- Nov 13th, 2023 1:05 pm
Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences
- Nov 9th, 2023 1:05 pm
We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate
- Nov 5th, 2023 2:57 pm
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
- Nov 3rd, 2023 8:05 pm
Terns Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity
- Nov 2nd, 2023 8:05 pm
Terns Pharmaceuticals to Participate in Upcoming Investor Conferences
- Oct 19th, 2023 8:05 pm
Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design of TERN-701 for the Treatment of Chronic Myeloid Leukemia
- Oct 16th, 2023 12:05 pm
Scroll